Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810245 · ClinicalTrials.gov registry record · Phase 1
Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain
A Phase 1 study of Chronic Low Back Pain and Chronic Osteoarthritis Pain, sponsored by Contineum Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 5
- Study locations
NCT06810245: Completed Phase 1 study of Chronic Low Back Pain and Chronic Osteoarthritis Pain, sponsored by Contineum Therapeutics.
NCT06810245 is a Phase 1 study of Chronic Low Back Pain and Chronic Osteoarthritis Pain that has completed, run by Contineum Therapeutics. The registered enrollment target is 43 participants, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06810245, a Phase 1 study of Chronic Low Back Pain and Chronic Osteoarthritis Pain, has completed, sponsored by Contineum Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.
Primary Outcome
The number of subjects with TEAEs will be summarized in each treatment arm and compared within each treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PIPE-791
Study Locations (5)
Arizona
- Arizona Research Center - Phoenix
Georgia
- Drug Studies America - Marietta
New York
- Drug Trials America - Hartsdale
Pennsylvania
- Altoona Center of Clinical Research - Duncansville
Utah
- JBR Clinical Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2026-01-20 |
| Phase | Phase 1 |
What the finished NCT06810245 record still lists
NCT06810245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Chronic Low Back Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06810245 lists 5 locations in 5 states (Arizona, Georgia, New York).
Frequently Asked Questions
What is clinical trial NCT06810245 about?
NCT06810245 is a clinical study titled "Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain". The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout pe...
What is the current status of trial NCT06810245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2025-02-04. Estimated completion is 2026-01-20.
What conditions does trial NCT06810245 study?
This clinical trial studies the following conditions: Chronic Low Back Pain, Chronic Osteoarthritis Pain.
What interventions are being tested in trial NCT06810245?
The interventions under investigation include: Placebo (DRUG), PIPE-791 (DRUG).
Who is sponsoring clinical trial NCT06810245?
This trial is sponsored by Contineum Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810245 being conducted?
This trial has 5 study locations across Arizona, Georgia, New York, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Low Back Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06810245's enrollment target sits among peer trials
43 50th of 71 higher than 21 of 71 other Chronic Low Back Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Low Back Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin Therapy for Chronic Low Back Pain
RECRUITING · Phase 1
-
Psilocybin in Chronic Low Back Pain and Depression
RECRUITING · Phase 1
-
Integrative Breathwork Intervention for Chronic Pain
RECRUITING · Phase 1
-
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
RECRUITING · Phase 1
-
Mobile Neurofeedback for Low Back Pain
RECRUITING · NA
-
Phenotyping Response to Spinal Cord Stimulation in Chronic Low Back Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI